Official NIH NLM MEDLINE / PubMed Citation • PMID: 42976160
Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis
PloS one
Verbatim Formal Study Abstract
Although ICIs are superior to chemotherapy in both sexes, the PFS benefit of ICI monotherapy appears to be attenuated in females relative to males.